文献速递肺外科

第九版TNM分期在IA-IIIA期非小细胞肺癌肺叶切除术中的外部验证

Validation of the 9th edition of the TNM staging system for non-small cell lung cancer with lobectomy in stage IA-IIIA.
PubMed 文献 · Eur J Cardiothorac Surg · 2024-01-01

研究基于SEER数据库19 193例接受肺叶切除术的IA-IIIA期非小细胞肺癌患者,外部验证并比较第9版与第8版TNM分期。第9版能更好区分IB与IIA期生存曲线(P<0.0001),且相邻分期区分更均匀,但两版预测精度相近,第9版合理有效。

要点

  • 第9版TNM分期可更好区分IB与IIA期患者生存曲线(P<0.0001)。
  • 第9版在单因素和多因素回归中区分相邻分期比第8版更均匀。
  • 第9版与第8版对总生存的预测能力与准确性相近。

核心结论

  • 外部验证表明第9版非小细胞肺癌TNM分期合理且有效。
  • 第9版TNM分期对非小细胞肺癌的预后准确性几乎与第8版相同。

研究设计与样本

  • 研究收集SEER数据库中19 193例接受肺叶切除术的IA-IIIA期非小细胞肺癌患者进行外部验证。
  • 采用Kaplan-Meier法比较TNM分期的生存,并用单因素和多因素Cox回归分析。
  • 使用受试者工作特征曲线评估模型准确性,并以Akaike信息准则、贝叶斯信息准则和一致性指数比较第8版与第9版TNM分期的预后预测能力。

主要发现

  • 第9版TNM分期系统在生存曲线上能更好区分IB与IIA期患者(P<0.0001)。
  • 在单因素和多因素回归分析中,第9版TNM分期系统比第8版能更均匀地区分任何两个相邻分期患者。
  • 第9版与第8版TNM分期对非小细胞肺癌患者总生存的预测能力和准确性相似:曲线下面积62.4 vs 62.3;Akaike信息准则166 182.1 vs 166 131.6;贝叶斯信息准则166 324.3 vs 166 273.8;一致性指数0.650(0.003)vs 0.651(0.003)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The 9th edition of tumour-node-metastasis (TNM) staging for lung cancer was announced by Prof Hisao Asamura at the 2023 World Conference on Lung Cancer in Singapore. The purpose of this study was to externally validate and compare the latest staging of lung cancer. METHODS: We collected 19 193 patients with stage IA-IIIA non-small cell lung cancer (NSCLC) who underwent lobectomy from the Surveillance, Epidemiology and End Results database. Survival analysis by TNM stages was compared using the Kaplan-Meier method and further analysed using univariable and multivariable Cox regression analyses. Receiver operating characteristic curves were used to assess model accuracy, Akaike information criterion, Bayesian information criterion and consistency index were used to compare the prognostic, predictive ability between the current 8th and 9th edition TNM classification. RESULTS: The 9th edition of the TNM staging system can better distinguish between IB and IIA patients on the survival curve (P < 0.0001). In both univariable and multivariable regression analysis, the 9th edition of the TNM staging system can differentiate any 2 adjacent staging patients more evenly than the 8th edition. The 9th and the 8th edition TNM staging have similar predictive power and accuracy for the overall survival of patients with NSCLC [TNM 9th vs 8th, area under the curve: 62.4 vs 62.3; Akaike information criterion: 166 182.1 vs 166 131.6; Bayesian information criterion: 166 324.3 vs 166 273.8 and consistency index: 0.650 (0.003) vs 0.651(0.003)]. CONCLUSIONS: Our external validation demonstrates that the 9th edition of TNM staging for NSCLC is reasonable and valid. The 9th edition of TNM staging for NSCLC has near-identical prognostic accuracy to the 8th edition.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Wang RR, Li MJ, Peng Q, et al. Validation of the 9th edition of the TNM staging system for non-small cell lung cancer with lobectomy in stage IA-IIIA. Eur J Cardiothorac Surg. 2024. PMID: 38426334. doi:10.1093/ejcts/ezae071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。